In a phase 2 randomised dose-finding study of oral NEPA in 65 evaluable children receiving highly or moderately emetogenic chemotherapy, overall complete response was 70.6% with netupitant 1.33 mg/kg and 67.7% with 4 mg/kg; no new safety signals were seen.
RCTn = 65
Patel et al. A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancer